DPYSL3

(redirected from ULIP)
Also found in: Acronyms, Wikipedia.

DPYSL3

A gene on chromosome 5q32 that encodes a member of the collapsin response mediator protein family that forms homotetramers and heterotetramers with CRMP1, DPYSL2, DPYSL4 or DPYSL5, interacting with synaptic vesicle protein 2 and SH3A domain of intersectin. DPYSL3 is necessary for signalling by class-3 semaphorins and subsequent cytoskeletal remodelling; it plays a role in axon guidance, neuronal growth cone collapse and cell migration.
Mentioned in ?
References in periodicals archive ?
The existing ULIP product 'Fortune Builder' has already shown excellent results with its NAV at $19 giving a cumulative aggregate growth rate of about 30 per cent.
Because of this feature, it will be in direct completion with ELSS mutual funds, but all the flexible aspects of the ULIPs will maintained.
Sanjay Tripathy, Senior EVP-Marketing, Product, Digital & Ecommerce, HDFC Life, said, We are extremely delighted to bring to our customers Click2Invest ULIP, a most convenient, transparent and cost-effective online buying experience, which we feel will transform the way life insurance-cum-savings plans are bought in our country.
Taking advantage of investor greed, life insurance companies started selling some ULIP products, in which the cost of purchase and maintenance was very high.
BO), has launched an innovative unit linked product, Smart ULIP.
Insurance regulator IRDA (Insurance Regulatory and Development Authority) in 2010, set out its customer aimed regulatory changes by introducing charge cap regulations by making ULIPs cost efficient compared to earlier versions.
In 2010, the IRDA introduced restrictions to the sale and structure of ULIPs, which caused sales to decline drastically.
In order to maintain high customer satisfaction levels, the Company under its SMART Solutions umbrella has launched three products - one traditional endowment plan and two ULIPs in line with the new regulatory guidelines.
Stock Market and Insurance regulators SEBI and IRDA were at loggerheads over the jurisdiction of hybrid insurance products like ULIPs with both claiming their authority over these popular schemes.
In part because of the move against the sales of ULIPs, partly because of more general uncertainty over the regulator's view in relation to single-premium products and partly due to an exodus of agents from the industry, new business premiums shrunk in the year ending March 2012 (which is identified as 2011 in the tables in this report).
in, says apart from versatility and convenience, MFs are the lowest cost option for wealth creation when compared to Ulips and structured products.
A regulatory cap on Ulips had in 2010 stopped the industry's growth, and many foreign stakeholders exited similar ventures in India.